About these reports
Using data derived from Beacon as of 4th of January 2022, the following series provides analysis of the existing DDR landscape, an overview of what happened in 2022, and a look at what the future might bring.
The two part analysis is split into:
- The Clinical Trial Landscape – Recap of 2022, top disease indications, combination trials and more
- The Drug Landscape – Developmental status, targets and more
To conclude our landscape review series, we will be hosting a complimentary webinar with the Beacon DDR team to provide additional analysis on the reports.
How the most complete DDR database can help you
What we cover
Beacon DNA Damage Response (DDR) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics targeting key points in DNA damage response pathways.
This module identifies drugs utilizing the concept of synthetic lethality, and covers DDR repair pathway components, including:
- Damage Sensors
- Signalling/Mediator Proteins
- Effector Proteins
- Cell Cycle Checkpoints
- DNA Metabolism when in relation to repair and recombination
Several key therapeutic targets in the DDR landscape included in this module are:
How Beacon DDR works
Search the trial and drug landscape by target, repair pathway and mechanism of action alongside 15 other search criteria including disease, line of therapy, biomarker, sponsor etc. to instantly extract the data points you need to conduct more complex analysis.